linjc16/ctgov huggingface dataset:
Autologous Platelet Gel in Wound Healing of Coronary Artery Bypass Grafting (CABG) Patients

Study Overview
=================
Brief Summary
-----------------
This study will determine if autologous platelet gel (APG) on sternal incision and conduit sites will improve wound healing and decrease infection in coronary artery bypass grafting surgery patients.

Detailed Description
-----------------
The purpose of this study is to determine if the use of autologous platelet gel (APG) on sternal incision and conduit sites will improve wound healing and decrease the incidence of infection in patients undergoing coronary artery bypass grafting surgery

Official Title
-----------------
Autologous Platelet Gel in Wound Healing of Coronary Artery Bypass Grafting (CABG) Patients

Conditions
-----------------
Wounds, Infection

Intervention / Treatment
-----------------
* Biological: autologous platelet gel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient who meets criteria and consents to undergo a CABG procedure involving conduit sites and consents to this study. Exclusion Criteria: Any patient, after inclusion, whom is later determined to have had on-going therapy that could influence wound healing such as radiation or chemotherapy, extensive steroid use, or accidental trauma such as burns, etc.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Platelet Gel<br>Participants receive platlet gel. | Biological: autologous platelet gel<br>* Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.<br>|
| Placebo Comparator: Control (No platelet gel)<br>Participants do not receive platlet gel. | Biological: autologous platelet gel<br>* Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Healing and infection of surgical sites | The surgical sites will be assessed for degree of healing and signs and symptoms of infection on post-op days one and three and during the patients' follow up visits in the clinic. | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
surgical site healing treated with autologous platlet gel
Differences in Ovarian Aging Between Caucasian and Indian Women

Study Overview
=================
Brief Summary
-----------------
The investigators want to carry out a prospective study of 400 infertile Caucasian and Indian women who will undergo a controlled ovarian stimulation for in vitro fertilization (IVF). The investigators will collect data about ovarian reserve markers and also the results after ovarian stimulation in both ethnic groups.The aim is to identify differences in ovarian response after IVF stimulation between both groups.

Detailed Description
-----------------
A total of 200 Caucasian patients and 200 Indian patients who will attend the first or second IVF cycle will be included. The date we will collect in both groups include the age, the body mass index, and the ovarian reserve markers like the antral follicle count (AFC), the follicle stimulation hormone (FSH) and antimullerian hormone (AMH) serum levels. The investigators will also determine the number of oocytes retrieved and the metaphase two oocytes in both groups after IVF stimulation.

Official Title
-----------------
Ethnicity as a Determinant of Ovarian Aging: Differences Between Caucasian and Indian Women

Conditions
-----------------
Age of the Patients and the Body Mass Index in Both Groups

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women aged < 42 years old, with both ovaries present, undergoing a first or second IVF treatment due to male factor, tubal disease or previous failed intrauterine insemination (IUI). Exclusion Criteria: Women diagnosed of polycystic ovary syndrome according to Rotterdam criteria, endometriosis stage III-IV, or previous pelvic inflammatory disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 42 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Caucasian women<br>200 Caucasian infertile women undergoing their first or second IVF cycle | |
| Indian women<br>200 Indian women undergoing their first or second IVF cycle. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AMH levels produced by granulosa cells | AMH levels (ng/mL) as well as AFC in both ethnic groups. | day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of oocytes | The number of oocytes retrieved as well as the mature oocytes after IVF ovarian stimulation | day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AMH, AFC, aging, ethnicity
Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find how much hyaluronidase should be used when receiving injections of fillers.

Official Title
-----------------
Pilot Study of Appropriate Dosing for Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase: A Randomized Control Clinical Trial

Conditions
-----------------
Drug Safety

Intervention / Treatment
-----------------
* Drug: Hyaluronidase


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 and over The subjects are in good health The subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator Exclusion Criteria: Under 18 years of age Pregnancy or Lactation Subjects who are unable to understand the protocol or to give informed consent Subjects with mental illness Recent Accutane use in the past 6 months Subjects prone to hypertrophic and keloidal scarring Subjects with tattoos and/or scars on upper medial arms (the treatment area) Subjects with known hypersensitivity to hyaluronic acid

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dose of Hyaluronidase<br> | Drug: Hyaluronidase<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dose of hyaluronidase injected until the filler is no longer detectable |  | 2 weeks |
A Switch Study of BMS-337039 in Schizophrenic Out-patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical research study is to evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing efficacy and/or safety/tolerability issues while on risperidone.

Official Title
-----------------
A Comparative, Randomized, Open-Label, Multicenter Study on the Efficacy and Safety of Switch Treatment With Aripiprazole in Schizophrenic Out-patients Who Are Experiencing Insufficient Efficacy With Risperidone and/or Safety and Tolerability Issues, While on Risperidone

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: Aripiprazole
* Drug: Aripiprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR2 criteria Out-patients who have been taking Risperidone for minimum 6 weeks who are not optimally controlled and/or experiencing safety/tolerability issues with Risperidone Men and women, aged 18 - 65 years Exclusion Criteria: Patients who are at risk for committing suicide Patients with a diagnosis of schizoaffective disorder, bipolar disorder, depression with psychotic symptoms, or organic brain syndromes Meeting DSM-IV-TR criteria for any significant Psychoactive Substance Use Disorder within the 3 months prior to Screening Treatment-resistant to antipsychotic medication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A1<br> | Drug: Aripiprazole<br>* Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.<br>* Other names: Abilify;|
| Active Comparator: A2<br> | Drug: Aripiprazole<br>* Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.<br>* Other names: Abilify;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients who discontinue because of Adverse Events |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Clinical Global Impression scale, Investigator Assessment Questionnaire, cognitive functioning and outcome research assessments at endpoint |  |  |
Screening for Silent Atrial Fibrillation During Influenza Vaccination

Study Overview
=================
Brief Summary
-----------------
Silent atrial fibrillation is an important cause of unnecessary strokes. If diagnosed and treated in time with anticoagulants, many disabling strokes can be prevented. In order to improve the diagnosis of atrial fibrillation the MyDiagnostick is developed; a user friendly and easy to use stick that diagnoses atrial fibrillation in one minute. During influenza vaccination, many patients who are also at risk for atrial fibrillation visit the general practice. This offers an ideal opportunity for screening for atrial fibrillation. The study investigates the yield of screening for atrial fibrillation with the MyDiagnostick during influenza vaccination (newly detected atrial fibrillation with corresponding CHA2DS2-Vasc score).

Official Title
-----------------
Screening for Silent Atrial Fibrillation During Influenza Vaccination

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Device: 'MyDiagnostick


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eligible for influenza vaccination Exclusion Criteria: Not eligible for influenza vaccination
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Screening with MyDiagnostick<br>All patients eligible for influenza vaccination are screened for atrial fibrillation with the MyDiagnostick, an easy to use and patient friendly device. | Device: 'MyDiagnostick<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Newly detected AF |  | during influenza vaccination | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Silent atrial fibrillation, primary care, screening, influenza vaccination
Treatment of Phimosis With Topical Steroid Cream -Double-blind, Randomized, Placebo-controlled Study

Study Overview
=================
Brief Summary
-----------------
During last years topical steroid creams have been suggested to be effective treatment for non-retractable foreskin instead of circumcision. Aim of this study is to investigate the efficacy, safety and persistence of treatment results of a medium potent steroid cream in a double-blind, randomized, placebo-controlled study.

Official Title
-----------------
Treatment of Phimosis With Topical Steroid Cream -Double-blind, Randomized, Placebo-controlled Study in 98 Boys

Conditions
-----------------
Phimosis

Intervention / Treatment
-----------------
* Drug: Mometasone furoate cream
* Drug: moisturizing cream


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: non-retractable foreskin requiring treatment Exclusion Criteria: age under six years old, previous operation or steroid treatment for phimosis

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: mometasone furoate cream<br>The study patient consecutive patients who were referred to outpatient clinic of Pediatric surgery for surgical treatment of non-retractable foreskin. The study patients were randomized to have either mometasone cream or placebo | Drug: Mometasone furoate cream<br>* Study cream was applicated once per day for 4-8 weeks.<br>* Other names: topical steroid cream;Drug: moisturizing cream<br>* study cream was applicated once per day for 4 to 8 weeks<br>* Other names: Novalan;|
| Placebo Comparator: moisturizer<br> | Drug: Mometasone furoate cream<br>* Study cream was applicated once per day for 4-8 weeks.<br>* Other names: topical steroid cream;Drug: moisturizing cream<br>* study cream was applicated once per day for 4 to 8 weeks<br>* Other names: Novalan;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retractability of foreskin |  | 4-16 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
phimosis,, non-retractable foreskin, topical steroids, children
Vitamin D Pilot Study in Patients With Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
Phase 1 study of 19-nor Vitamin D in relapsing-remitting MS. Primary measure is MRI.

Official Title
-----------------
Vitamin D Pilot Study in Patients With Multiple Sclerosis

Conditions
-----------------
Relapsing Remitting Multiple Sclerosis

Intervention / Treatment
-----------------
* Drug: 19 nor vitamin d


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: relapsing remitting MS Exclusion Criteria: MRI contraindicated

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 19 nor vitamin d<br> | Drug: 19 nor vitamin d<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MRI Measure of new active lesions, observation vs. treatment |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vitamin D, 19 nor Vitamin D, Multiple Sclerosis
Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the Headache Disability Questionnaire

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to investigate cultural adaptation, reliability and validity of the Turkish version of the Headache Disability Questionnaire (HDQ).

Detailed Description
-----------------
When the outcome criteria for the physiotherapy of headache are considered in clinical studies and practice, parameters such as headache frequency, duration and severity are frequently used. Physiotherapists treat musculoskeletal dysfunction in various types of headache, including migraine, tension headache, and cervicogenic headache. The Headache Disability Questionnaire (HDQ), which was developed to measure the quality of life of a general population receiving physiotherapy and experiencing headache, evaluates the pain intensity, daily life activities, disruptions in work or school life, and the influence of the recreational activities of individuals. HDQ consists of 9 items and each item is rated between 0 and 10. Increasing the score indicates the seriousness of the impact. The study is planned with 45 individuals with gluteal tendinopathy. After questioning the sociodemographic characteristics of the individuals, the patients will be asked to fill in HDQ, Migraine Disability Assessment Questionnaire, Headache Impact Test-6 and Short Form-36.Test-retest will be re-applied to those of the same individuals who can be reached after 1 week. The results will be analyzed using the SPSS version 22.0 computer package program.

Official Title
-----------------
Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the Headache Disability Questionnaire

Conditions
-----------------
Headache, Headache Disorders, Headache, Migraine, Headache, Tension, Headaches Chronic, Headaches Muscular

Intervention / Treatment
-----------------
* Other: Survey study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with any type of headache, Have a chronic headache. Exclusion Criteria: Having a cognitive and neurological disorder.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients group<br>Individuals with headache | Other: Survey study<br>* Headache Disability Questionnaire (HDQ) will be applied.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Headache Disability Questionnaire (HDQ) | Headache Disability Questionnaire is designed to measure the quality of life related to the disability. | 10 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Headache, Reliability, Validity, Cross-cultural adaptation
Validation of OxyVu for Assessing Level of Amputation With Comparison to Other Modalities

Study Overview
=================
Brief Summary
-----------------
Correlation of(OxyVu) values to to ABI, TBP, and TCOM in patients scheduled for foot level amputation because of critical limb ischemia, infection, or tissue necrosis.

Detailed Description
-----------------
The purpose of this clinical study is to correlate tissue oxygenation values measured with a hyperspectral imaging system (OxyVu) to Ankle Brachial Indices (ABI), toe pressures (TBP), and transcutaneous oxygen monitoring (TCOM) in patients scheduled for foot level amputation because of critical limb ischemia, infection, or tissue necrosis.

Official Title
-----------------
Clinical Validation of HyperMed OxyVu Tissue Oximeter for Assessing Level of Amputation With Comparison to Other Modalities

Conditions
-----------------
Critical Limb Ischemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 to 85 years of age, males and females, varying skin tones, varying racial origins, and with and without diabetes. Patients scheduled for foot level amputation because of critical limb ischemia, infection, or tissue necrosis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess predictive value for healing by 8 weeks of OxyVu, ABI, TBI and TCOM measured prior to amputation. OxyVu readings for oxyhemoglobin, deoxyhemoglobin and oxygen saturation will be compared to healing potential predicted from ABI, TBI, and TCOM. |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collect additional interventions required through review of patient medical records at 12 months |  | 12 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hyperspectral imaging, tissue oxygenation, foot amputation, critical limb ischemia, tissue necrosis